Australia markets closed

GSK Jan 2024 45.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.08000.0000 (0.00%)
As of 10:02AM EDT. Market open.
Full screen
Previous close0.0800
Expiry date2024-01-19
Day's range0.0800 - 0.0800
Contract rangeN/A
Open interest1.61k
  • Zacks

    Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

    Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.


    FDA approves GSK's unique myelofibrosis treatment Ojjaara

    The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.


    FDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemia

    The FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on Monday. The approval comes following a three-month delay due to an FDA request for additional information.